PPT-Ledipasvir-Sofosbuvir +/- 3
rd DAA in HCV Genotype 1 NIAID SYNERGY Genotype 1 Phase 2 Treatment Naïve unfavorable baseline treatment characteristics Kohli A et al Lancet 2015385110713 Source
Download Presentation
"Ledipasvir-Sofosbuvir +/- 3" is the property of its rightful owner. Permission is granted to download and print materials on this website for personal, non-commercial use only, provided you retain all copyright notices. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
Transcript not available.